Research: Improving treatment of patients with heart attack

Jun 25, 2009

When faced with patients suffering a heart attack, doctors have two choices: inject them with medication to dissolve the blood clot (fibrinolytic therapy) or insert a small balloon to open the blocked artery (primary percutaneous coronary intervention (PCI)).

Guidelines for treating heart attacks are generally based on clinical trials that do not take "real-life" conditions into account. The latest study by Dr. Thao Huynh of the Research Institute of the MUHC analyses these gaps and provides potential solutions to improve of heart attack. Her article was published in the June 23rd issue of Circulation.

In this study, Dr. Huynh compares the results of 23 randomized controlled trials conducted under controlled experimental conditions, with the results of 32 observational studies reporting on the treatment of with heart attacks in routine clinical conditions.

Both types of studies show the superiority of PCI over fibrinolytic therapy in reducing mortality and the risk of further episodes of and stroke over the short term. However, the advantage of PCI is even more apparent in randomized controlled trials where delays in providing primary PCI are shorter than in routine clinical conditions.

"This study indeed demonstrates that we have to work to reduce these delays if we are to maximize the effectiveness of PCI," explained Dr. Huynh. "When it comes to treating heart attack, reducing delays in providing treatment is the number one priority. It is also essential that patients with symptoms of heart attack seek prompt medical attention. Delays by patients to seek medical attention may further increase delays to treatment of heart attack. "

Analysis of randomized controlled trials shows that primary PCI also reduces long-term mortality and repeat heart attack. However, this long-term benefit of primary PCI is not observed in observational studies where patients receive treatment within routine clinical conditions.

"The benefit of primary PCI can be lost over the long term if patients are not receiving optimal medical therapy after discharge from hospital. These medications are essential to prevent repeat ." warned Dr. Huynh.

Source: McGill University (news : web)

Explore further: Mice study shows efficacy of new gene therapy approach for toxin exposures

add to favorites email to friend print save as pdf

Related Stories

Delayed angioplasty -- big bucks, no bang

Nov 05, 2007

In a subset of patients suffering heart attack, adding stents to clot-busting medical therapy after the optimal treatment window ends isn't justified, say researchers from Duke University Medical Center.

Stenting not necessary in late treatment of heart attacks

Feb 18, 2009

Two years ago, a major study found that many patients who receive delayed treatment for a heart attack do just as well with drugs alone as they do with drugs plus stents to prop open their blocked arteries. Now, further analysis ...

Novel compound may lessen heart attack damage

Feb 07, 2008

A novel drug designed to lessen muscle damage from a heart attack has passed initial safety tests at the Duke Clinical Research Institute. Results of the study, available online and to be published in the February 19 issue ...

Recommended for you

How Alzheimer's peptides shut down cellular powerhouses

Aug 29, 2014

The failing in the work of nerve cells: An international team of researchers led by Prof. Dr. Chris Meisinger from the Institute of Biochemistry and Molecular Biology of the University of Freiburg has discovered ...

User comments : 0